Literature DB >> 1065299

Evaluation of an enteric coated aspirin preparation.

R O Day, P D Paull, G D Champion, G G Graham.   

Abstract

The bioavailability and gastrointestinal site of release of enteric coated aspirin tablets ("Rhusal", G.P. Laboratories) were investigated following dosage with single tablets. A delay of one to more than eight hours was observed between dosage and the appearance of salicylate in plasma or saliva. This delay was decreased by pretreatment with metoclopramide. No aspirin or salicylate was detected in gastric aspirates. The mean urinary recovery of salicylate was equivalent to 92% of the administered dose. All these tests were consistent with the designed function of the enteric coating. The time course of concentrations of salicylate in saliva rather than in plasma was confirmed as a useful technique for the evaluation of different formulations of aspirin. The acceleration of gastric emptying by metoclopramide is a useful technique for the evaluation of enteric coated tablets.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1065299     DOI: 10.1111/j.1445-5994.1976.tb03290.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  4 in total

1.  Visualization of the small intestine using capsule endoscopy in healthy subjects.

Authors:  Akiko Shiotani; Antone R Opekun; David Y Graham
Journal:  Dig Dis Sci       Date:  2007-02-16       Impact factor: 3.199

2.  Influence of food on the absorption of acetylsalicylic acid from enteric-coated dosage forms.

Authors:  C Bogentoft; I Carlsson; G Ekenved; A Magnusson
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

3.  The influence of food on the absorption of diclofenac after single and multiple oral doses.

Authors:  J V Willis; M J Kendall; D B Jack
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of the salicylates.

Authors:  C J Needs; P M Brooks
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.